Literature DB >> 16305493

SARS: understanding the virus and development of rational therapy.

K Stadler1, R Rappuoli.   

Abstract

In late 2002 a new disease, severe atypical respiratory syndrome (SARS), emerged in China. A hitherto unknown animal coronavirus (CoV) that had crossed the species barrier through close contact of humans with infected animals was identified as the etiological agent. It rapidly adapted to the new host and not only became readily transmissible between humans but also more pathogenic. Air travel spread it rapidly around the world and ultimately the virus infected 8096 people and caused 774 deaths in 26 countries on 5 continents. Aggressive quarantine measures successfully terminated the disease. Currently, there are no SARS cases recorded and most likely the virus no longer circulates in the human population. In this review we present an overview over SARS-Co virus biology, the disease and discuss strategies to develop antiviral drugs and vaccines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16305493     DOI: 10.2174/156652405774641124

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  8 in total

1.  Highly conserved regions within the spike proteins of human coronaviruses 229E and NL63 determine recognition of their respective cellular receptors.

Authors:  Heike Hofmann; Graham Simmons; Andrew J Rennekamp; Chawaree Chaipan; Thomas Gramberg; Elke Heck; Martina Geier; Anja Wegele; Andrea Marzi; Paul Bates; Stefan Pöhlmann
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Coronavirus escape from heptad repeat 2 (HR2)-derived peptide entry inhibition as a result of mutations in the HR1 domain of the spike fusion protein.

Authors:  Berend Jan Bosch; John W A Rossen; Willem Bartelink; Stephanie J Zuurveen; Cornelis A M de Haan; Stephane Duquerroy; Charles A B Boucher; Peter J M Rottier
Journal:  J Virol       Date:  2007-12-12       Impact factor: 5.103

3.  Therapeutic Development in COVID-19.

Authors:  Chan Yang; Yuan Huang; Shuwen Liu
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research.

Authors:  Graham Simmons; Pawel Zmora; Stefanie Gierer; Adeline Heurich; Stefan Pöhlmann
Journal:  Antiviral Res       Date:  2013-10-08       Impact factor: 5.970

5.  IFITM proteins inhibit entry driven by the MERS-coronavirus spike protein: evidence for cholesterol-independent mechanisms.

Authors:  Florian Wrensch; Michael Winkler; Stefan Pöhlmann
Journal:  Viruses       Date:  2014-09-26       Impact factor: 5.048

Review 6.  SARS-CoV, MERS-CoV and SARS-CoV-2 infections in pregnancy and fetal development.

Authors:  Guilherme Antonio de Souza Silva; Suéllen Pedrosa da Silva; Marcos Aurélio Santos da Costa; Abdênego Rodrigues da Silva; Robson Raion de Vasconcelos Alves; Fernanda das Chagas Ângelo Mendes Tenório; Alanne Rayssa da Silva Melo; Antonio Carlos de Freitas; Cristiane Moutinho Lagos de Melo
Journal:  J Gynecol Obstet Hum Reprod       Date:  2020-06-26

7.  Genome-wide analysis of protein-protein interactions and involvement of viral proteins in SARS-CoV replication.

Authors:  Ji'an Pan; Xiaoxue Peng; Yajing Gao; Zhilin Li; Xiaolu Lu; Yingzhao Chen; Musarat Ishaq; Dan Liu; Marta L Dediego; Luis Enjuanes; Deyin Guo
Journal:  PLoS One       Date:  2008-10-01       Impact factor: 3.240

8.  COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics.

Authors:  Dhanusha Yesudhas; Ambuj Srivastava; M Michael Gromiha
Journal:  Infection       Date:  2020-09-04       Impact factor: 7.455

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.